Gefitinib-induced disseminated intravascular coagulation in a patient with non-small cell lung cancer

In February 2005, Gefitinib （Iressa）, a small-molecular .epidermal growth factor receptor and tyrosine kinaseinhibitor, was approved in China as an anticancer agent for patients with advanced （local or metastatic） non-small cell lung cancer （NSCLC）, who failed prior chemotherapy. The common adverse...

Full description

Saved in:
Bibliographic Details
Published in:Chinese medical journal 2010-02, Vol.123 (4), p.505-506
Main Authors: Yuan, Guang-jin, Ke, Qin-hua, Xu, Xi-ming, Yang, Ji-yuan, Su, Xiao-yan
Format: Article
Language:English
Subjects:
Aged
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Carcinoma, Non-Small-Cell Lung - drug therapy
Disseminated Intravascular Coagulation - chemically induced
Female
Humans
Quinazolines - adverse effects
Quinazolines - therapeutic use
不良反应
严重程度
皮肤瘙痒
血管内凝血
表皮生长因子受体
非小细胞肺癌
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In February 2005, Gefitinib （Iressa）, a small-molecular .epidermal growth factor receptor and tyrosine kinaseinhibitor, was approved in China as an anticancer agent for patients with advanced （local or metastatic） non-small cell lung cancer （NSCLC）, who failed prior chemotherapy. The common adverse events of the drug include acne-like skin rash, paronychia, pruritus, diarrhea, nausea/vomiting, anorexia, hepatitis, and hyperbilirubinemia.1 However, these adverse events are generally mild in severity and reversible on cessation of the treatment. Therefore, gefitinib has been regarded as a relatively safe agent,
ISSN:0366-6999
2542-5641
DOI:10.3760/cma.j.issn.0366-6999.2010.04.022